Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
about
Quality of life in patients with psoriasisOutcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Psoriasis (chronic plaque)Anti-TNF-alpha agents in the treatment of psoriatic arthritis.New treatments for psoriasis: which biologic is best?TNFalpha blockade in human diseases: an overview of efficacy and safety.Infliximab for the treatment of psoriasis.Psoriasis comorbidities.Treatment of severe psoriasis with infliximab.Infliximab for the treatment of plaque psoriasis.A critical review of human endotoxin administration as an experimental paradigm of depression.Depression and quality of life in psoriasis.Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment.Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.Cost effectiveness of biologic therapies for plaque psoriasis.Biological therapies for psoriasis.A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.A Review of Psoriasis, Therapies, and Suicide.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO).Identification of psoriatic patients at risk of high quality of life impairment.Meta-analysis: rapid infliximab infusions are safe.Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials.
P2860
Q21245617-5F7F219F-ADA8-4357-81F1-AE5081B9F76EQ33301650-1D0EBE89-3FC4-4975-A209-4919A22072EEQ33785083-63EA4BDF-7EAD-4DE9-BE12-2C178198B5BCQ34010557-1ECE1B60-19C5-4E3E-9B3A-245617B5EC19Q36377196-30C397A4-69FB-4607-8ED3-A2A3DE092A05Q36502882-623B0CF2-9DD8-47F1-84A4-66C8EC8DD82CQ36536861-EDE27129-BC5E-4E91-9C17-15F96CF2C940Q36541961-B015DC12-7A68-4FF0-9C66-0479A625D99CQ37084274-ED452061-416D-4B32-859D-38E666A32172Q37098135-2D597F50-F7A7-42A7-87FD-A7D5CEFD74BAQ37307554-4721222A-3A76-4B75-8F51-69C15BAD405EQ37481759-A236106C-ADBA-4113-9786-5C4D89DB01B3Q37566094-9AB0A23D-DFBB-460A-8383-8AB7DABC7797Q38030436-B6F2312E-8E92-4E63-83D5-7665217330F4Q38064467-4984D1A0-587F-46DB-B8DB-0989B0740BF7Q38108567-9C0704FD-CD16-49F3-9A08-8231280E86C9Q38155648-61D087D3-3DB2-44B7-934A-5D8999A0FC96Q38623340-6C7121BC-A0BB-4D00-A3AC-267B8BB990B3Q38840271-DBA51FA4-C6B0-45F1-B1D2-2854F3385685Q38858335-240D67FC-CF78-46E7-A370-349022DC565DQ39601823-A570B888-7EC6-421C-AF76-169850EA8F18Q43720865-945C93D4-3880-42AA-8BE2-1766012F48DBQ44554932-7AB67A25-ED02-4DE7-84B4-547A6698E442Q44771208-E4C13855-6328-4DDC-B429-8748A7362CB8Q47260366-8B2F58E2-534D-4E84-9341-0E96740AFDCEQ47644680-62FFF354-2729-48D8-A55C-4F96FB8EC329Q48065188-C694E7B8-C5BC-4DD2-8102-E7AF50D0A296Q48184749-CF9A1C0B-6DD7-4F4D-94D3-43CE76BB68CEQ48215570-72C9E560-F01C-4DC9-B567-0068F2ACAAEAQ48566723-42F2B970-81FA-479D-95A6-ABF66C1FDEEAQ49963125-FDC49A1E-760F-4209-AD87-C809A3E7F060Q51895102-4B8FE471-1805-4562-B804-3FCD4114A355Q51896431-670AE85C-B65C-41EB-9ECC-94808F9DF80BQ51917360-DEF184C4-65A0-4290-8C97-5AFF8B96B540Q53168250-1EBE88F5-F218-4B6C-9218-C3D3ACC913A6
P2860
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Infliximab treatment results i ...... lind placebo-controlled trial.
@en
Infliximab treatment results i ...... lind placebo-controlled trial.
@nl
type
label
Infliximab treatment results i ...... lind placebo-controlled trial.
@en
Infliximab treatment results i ...... lind placebo-controlled trial.
@nl
prefLabel
Infliximab treatment results i ...... lind placebo-controlled trial.
@en
Infliximab treatment results i ...... lind placebo-controlled trial.
@nl
P2093
P2860
P921
P1476
Infliximab treatment results i ...... lind placebo-controlled trial.
@en
P2093
Gottlieb AB
P2860
P304
P356
10.1111/J.1365-2133.2005.06510.X
P407
P577
2005-05-01T00:00:00Z